United Therapeutics UTHR · NASDAQ
$533.12 -1.55% (-$8.39)
Summary
88 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 23% a year over the last 3 years.
- Out of every 100 USD of revenue, 42 USD is left as net profit.
- It earns 18 USD a year on every 100 USD of invested capital.
- It has no debt and holds $1.80B in cash.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.5 USD for 1 USD of yearly profit. Over the last five years it was 16.6 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 18% a year. For the next fiscal year analysts expect revenue to fall by 0.7%. Earnings per share grew by 23% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 14 USD
- Research and development 17 USD
- Sales and administration 24 USD
- Taxes and other 2.9 USD
- Net profit 42 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 42 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 18
- Hold 11
- Sell 1
Today's price within the analysts' price targets
The average target of $622.5 is 17% above today's price. 60% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Tyvaso 59%
- Remodulin 17%
- Orenitram 16%
- Unituxin 7.1%
- Adcirca 0.9%
- Other 0.8%
By region
- UNITED STATES 95%
- Non-US 4.6%
Tyvaso brings in 59% of revenue.
Segments in detail